[1] RAHIB L, SMITH B D, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030:the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11):2913-2921. [2] EROL V, MAKAY Ö, CÖZG, et al. The importance of staging systems for the determination of prognosis of well-differentiated thyroid cancer[J].Ulus Cerrahi Derg, 2013,29(1):7-10. [3] NIX P, NICOLAIDES A, COATESWORTH A P. Thyroid cancer review 1:presentation and investigation of thyroid cancer[J]. Int J Clin Pract, 2005,59(11):1340-1344. [4] VITA R, IENI A, TUCCARI G, et al. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma[J].Rev Endocr Metab Disord, 2018,19(4):301-309. [5] KNÜPFER H, PREISS R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results[J]. Int J Colorectal Dism, 2010, 25(2):135-140. [6] 姜春霞, 陈阔. 胃癌患者血清中肿瘤坏死因子-α和白介素-6水平检测及其临床诊断价值[J]. 肿瘤基础与临床, 2017,30(1):74-75. [7] SANTER F R, MALINOWSKA K, CULIG Z, et al. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells[J]. Endocr Relat Cancer, 2010, 17(1):241-253. [8] YEH K Y, LI Y Y, HSIEH L L, et al. Analysis of the effect of serum interleukin-6(IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer[J]. Jpn J Clin Oncol, 2010, 40(6):580-587. [9] PROVATOPOULOU X, GEORGIADOU D, SERGENTANIS T N, et al. Interleukins as markers of inflammation in malignant and benign thyroid disease[J].Inflamm Res, 2014, 63(8):667-674. [10] CHUNG J H, LEE Y C, EUN Y G, et al. Single nucleotide polymorphism of interleukin-18 and interleukin-18 receptor and the risk of papillary thyroid cancer[J]. Exp Clin Endocrinol Diabetes, 2015,123(10):598-603. [11] 杨毅, 张洁, 王智勇,等. SHP2介导IL-6促进乳腺癌细胞侵袭作用机制的研究[J]. 中国肿瘤临床, 2016, 43(18):792-796. [12] LUMACHI F, BASSO S M M, ORLANDO R. Cytokines, thyroid diseases and thyroid cancer[J]. Cytokine, 2010,50(3):229-233. [13] HOLTE E, KLEVELAND O, UELAND T, et al. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction[J]. Heart, 2017,103(19):1521-1527. [14] BARTON B E, MURPHY T F. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen[J]. Cytokine, 2001,16(6):251-257. [15] TONG J, WANG Y, DA J P. Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions[J]. Zhonghua Zhong Liu Za Zhi, 2011,33(8):599-604. [16] ZHOU DH, LI Z, BAI X F. BRAFV600E and RET/PTC promote proliferation and migration of papillary thyroid carcinoma cells in vitro by regulating nuclear factor-κB[J]. Med Sci Monit, 2017,23:5321-5329. [17] HONG L L, QIN J S, HUANG J X, et al. Expression and significance of NF-κB p65 and CyclinD1 in papillary thyroid carcinoma[J]. Hainan Med J, 2014,11(12):1853-1855. [18] PRASAD S, RAVINDRAN J, AGGARWAL B B. NF-κB and cancer:how intimate is this relationship[J]. Mol Cell Biochem, 2010, 336(1/2):25-37. [19] VISCONTI R, CERUTTI J, BATTISTA S, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression[J]. Oncogene, 1997,15(16):1987-1994. [20] FAGIN J A. How thyroid tumors start and why it matters:kinase mutants as targets for solid cancer pharmacotherapy[J]. J Endocrinol, 2004,183(2):249-256. [21] RHODEN K J, UNGER K, SALVATORE G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes:follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma[J]. J Clin Endocrinol Metab, 2006,91(6):2414-2423. [22] WIRTSCHAFTER A, SCHMIDT R, ROSEN D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis[J]. Laryngoscope, 1997,107(1):95-100. |